



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/849,498	05/19/2004	Yi-Yan Yang	S1507.70000US00	6009
23628 7590 04/01/2009 WOLF GREENFIELD & SACKS, P.C. 600 ATLANTIC AVENUE BOSTON, MA 02210-2206				
EXAMINER HIBBERT, CATHERINE S				
ART UNIT		PAPER NUMBER		
1636				
MAIL DATE		DELIVERY MODE		
04/01/2009		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

10/849,498

**Applicant(s)**

YANG ET AL.

**Examiner**

CATHERINE S. HIBBERT

**Art Unit**

1636

**Period for Reply** -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 15 July 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1, 3-5, 8-16, 44 and 49-54 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1, 3-5, 8-16, 44 and 49-54 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB-08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 15 July 2008 has been entered.

Applicant's Amendments to the Claims, filed 15 July 2008, have been received and entered. Claims 2, 6-7, 17-43 and 45-48 are cancelled. Claim 54 is new. Claims 1, 3-5, 8-16, 44 and 49-54 are pending and under examination in this action.

### ***Claim Objections***

The objection to Claims 4 and 5 is withdrawn based on Applicants Amendment to the Claims filed 15 July 2008.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 3-5, 8-16, and 49-54 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 3-5, 8-16, and 50-54 are indefinite in reciting "an article" claim because one of ordinary skill in the art would not be able to determine whether these claims

require all that is required of the article of the base claim or alternatively whether these claims are drawn to only one potential embodiment of the base claim.

Claim 49 is indefinite in reciting "an kit as in claim 44" because one of ordinary skill in the art would not be able to determine whether these claims require all that is required of the kit of claim 44 or alternatively whether these claims are drawn to only one potential embodiment of claim 44.

Additionally, Claims 13, 14, and 16 are indefinite in reciting "the polymeric backbone" because neither Claims 1 nor Claim 11, from which Claims 13, 14 and 16 depend, refer to "a polymeric backbone". Rather, Claim 1 recites "a polymer having a backbone comprising a polyester". Therefore, one of ordinary skill in the art could interpret Claim 1 to encompass polymers having a backbone that itself was not polymeric or a polyester but that comprised "side-chain" polyesters, for example. Accordingly, these embodiments that are encompassed by a broad interpretation of the claims, as written, for the phrase "a polymer having a backbone comprising a polyester" might not necessarily be considered a "polymeric backbone".

Additionally, Claim 49 is indefinite in reciting the phrase "the polymer" because it is unclear whether the antecedent basis for "the polymer" is the reference to "the polymeric nanoparticle", which would inherently be a polymer, or is the reference to "the polymer having a backbone".

### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 1636

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1, 3-5, 8-16, 44 and 49-53 STAND rejected and newly added claims 54 is rejected under 35 U.S.C. 102(a) and 102(e) as being anticipated by Lollo et al, (USPGPub 2003/0134420A1, filed 2 August 2002, published 17 July 2003, see whole document, of record) for reasons of record and below.

Applicants arguments have been fully considered but are not found persuasive.

**Claim interpretation:** Claims must be given their broadest reasonable interpretation in light of the instant specification during examination. Accordingly, the terms such as “associated” must be given a very broad interpretation regarding the claim language in part because Applicant provides a broad description in the specification for how molecules may be associated and dissociated with one another for the claimed invention. Applicant recites: “A first molecule may be “associated” with a second molecule, under set conditions, if the two molecules move together as a unit under these conditions. For example, the two molecules may be immobilized with respect to each other. The two molecules may be covalently or ionically bonded, may be joined by Van der Waal's forces or magnetic forces or one molecule may be physically contained or trapped by the second molecule or a collection of second molecules” [instant specification ¶ 0048]. Applicant further recites: “A first molecule may

Art Unit: 1636

be "disassociated" from a second molecule or article with which it is associated.

Disassociated means that the first molecule can move independently of the second molecule. The first molecule can also be disassociated from a second molecule or from an article if the second molecule or article degrades or is broken down so that it is no longer linked to the first molecule" [instant specification ¶ 0049]. In addition, the t

Claim 1 is drawn to an article for delivering a drug and a nucleic acid, the article comprising: a nanoparticle forming a micelle, wherein the nanoparticle comprises a polymer having a backbone comprising a polyester; a nucleic acid associated with an exterior of the micelle; and a drug associated with an interior of the micelle (claim 1). Applicants further claim wherein the nucleic acid is DNA (claim 4), and wherein the article is in a composition with a pharmaceutically acceptable carrier (claim 10). Applicants also claim wherein the nanoparticle is capable of passing through a cell membrane, is stable at a concentration of greater than 5 mg/L (claims 3 and 8). Claim 11 is drawn to an article as in Claim 1 wherein the backbone comprises tertiary amines). Claim 15 further specifies within Claim 11 that at least a portion of the tertiary amines are quaternized and bound to a hydrophobic side chain. Claims 52 and 53 are drawn to an article as in Claim 1 wherein the drug is not covalently or ionically bound to the nanoparticle (Claim 52) and is physically contained by the nanoparticle (Claim 53). Newly added Claim 54 is drawn to an article as in Claim 1, wherein the polymer comprises a graft co-polymer.

Lollo et al teach wherein the article forms a micelle and further teach wherein a drug is associated with an interior of the micelle and a nucleic acid is associated with an

Art Unit: 1636

exterior of the micelle (claims 1 and 44). For example, Lollo et al recite "the invention provides novel molecular complexes, referred to as "polyplexes" containing an anionic compound, such as a nucleic acid, associated with one or, more typically, multiple co-polymer domains, including a cationic domain, a transitional domain, and/or a surface domain (§ 0005, lines 1-2).

As shown in FIG. 1, polyplexes of the present invention are made up of multiple co-polymer domains. These domains are organized by the type of functional groups present on the co-polymer making up the domain. Typically, **the center domain** (Zone I of FIG. 1) contains the anionic agent. Examples of anionic agents include nucleic acids, **negatively charged drugs** and other small molecules capable of being delivered via a polyplex through a cellular boundary or lipid membrane. The cationic domain (Zone II of FIG. 1) is designed to interact, e.g., electrostatically, with the anionic domain/agent. Generally, the cationic domain is comprised of one or more cationic backbone moieties of copolymers, which are described in greater detail below. The transitional domain (Zone III of FIG. 1) links the cationic domain with the surface domain, typically via linear or branched co-polymers. The transitional domain may be hydrophobic in nature and may be comprised, at least in part, of hydrophobic moieties of copolymers. When the transitional domain is comprised at least in part of hydrophobic moieties, it is generally referred to as the "hydrophobic domain." Finally, the surface domain (Zone IV of FIG. 1) defines the polyplex surface by way of, for example, branching elements which allow the introduction of multiple molecules or other polymers on the polyplex surface. Such moieties modify the surface properties of the polyplex so as to enhance overall delivery of the anionic agent. The surface domain may be comprised, at least in part, of hydrophilic moieties of copolymers, as well as other ligands and other surface moieties which allow the polyplex to perform its intended function [0032].

In addition, applicants claim the article in claim 1 wherein the drug is a cancer drug and wherein the article is in a composition with a pharmaceutically acceptable carrier (claims 5 and 10). Applicants also claim a kit comprising: a container including an amphoteric polymeric nanoparticle forming a micelle, wherein the polymeric nanoparticle comprises a polymer having a backbone comprising a polyester; a nucleic

acid associated with an exterior of the micelle, a drug associated with an interior of the micelle; and instructions for administering the nanoparticle to a subject (claim 44).

Lollo et al teach a micelle complex comprised of amphoteric nanoparticles having a hydrophilic portion associating with DNA and/or cancer drugs and a hydrophobic portion capable of associating with cancer drugs and capable of passing through a cell membrane and capable of being directed to specific membranes by receptor-mediated targeting. In addition, Lollo et al contemplate a multidomain complex which can accommodate nucleic acids either on the interior or exterior and can accommodate drugs either on the interior or exterior (claims 49-52). For example, Lollo et al recite: "Typically, the center domain (Zone I of FIG. 1) contains the anionic agent. Examples of anionic agents include nucleic acids, negatively charged drugs and other small molecules capable of being delivered via a polyplex through a cellular boundary or lipid membrane" (¶ 0032, lines 2-4 and especially ¶ 0031-0038).

Furthermore, Lollo et al anticipate using their invention to treat a subject and although they do not explicitly recite "instructions", it would be inherent that any treatment plan for treating a human subject would inherently require instructions. For example, Lollo et al recite "A method for treating a subject comprising administering to said subject an effective amount of a penetration enhancer and a polyplex comprising a nucleic acid, a cationic backbone moiety, a hydrophobic moiety, and a hydrophilic moiety, such that said subject is treated" (e.g. see Lollo et al claims 58, 59 and 68). Lollo et al anticipate using the complex to deliver genes and drugs *in vivo* and thus anticipate claims 10 and 44.



Furthermore Lollo et al teach wherein the article forms a micelle and further teaches wherein a drug is associated with an interior of the micelle and a nucleic acid is associated with an exterior of the micelle (claims 1 and 44). For example, Lollo et al teaches partially hydrophobic conjugates also may be used since they possess moieties that preserve sufficient water solubility (since purely hydrophobic molecules are water insoluble). These conjugates can be made up of two different types of grafts, hydrophilic moieties to maintain adequate water solubility ('A'), and hydrophobic moieties ('B') to introduce a domain with binding and micelle formation properties. In one embodiment, the polymer is designed by grafting two or more of these elements onto a cationic backbone moiety (e.g., a cationic polymer, 'C') (claims 49-51). A suitable grafting element, or hydrophilic moiety for this approach is PEG, which promotes solubility and steric shielding. Another suitable grafting element is any hydrophobic moiety, as described above, which may form domains with binding capabilities. These two or more types of grafting elements can then be randomly distributed along a cationic backbone moiety during the grafting step (§ 0067, lines 1-6).

In addition, Lollo et al teaches an article as in claim 1 wherein the nanoparticle is stable at a concentration of greater than 5 mg/L because Lollo et al recites "polyplex concentration are reported by DNA content and were 10 ug/ml" which reads on the instant claim 8.

Furthermore, Lollo et al teach an article as in claim 1 wherein the nanoparticle comprises a graft co-polymer having a backbone including tertiary amines, at least a portion of the tertiary amines quaternized and bound to a hydrophobic side chain (claim

11), and further teaches wherein the hydrophobic side chain comprises cholesterol (claims 12 and 54). For example, Lollo et al teaches FIG. 11 shows the structure of grafted polymers with two hydrophobic domains per PEG chain. FIG. 11a shows a hydrophobic domain between the cationic domain and the surface domain. FIG. 11b shows a hydrophobic domain positioned at the terminus of a surface (e.g., hydrophilic) domain, and between the surface (e.g., hydrophilic) and cationic domains (¶ 0023, lines 1-3) (claims 49-53).

***Response to Applicants Amendments/Arguments***

**Applicants response** (see REMARKS, 7/15/2008) is that Applicant has amended independent claims 1 and 44 to include a nanoparticle comprising a polymer having a backbone comprising a polyester. Applicant states that "this feature was recited in original claim 15, and is not taught or suggested by Lollo". Furthermore, Applicants argue that "while Lollo teaches the use of activated esters (e.g., paragraph 64), the activated esters react to form an amide bond and, therefore, do not form a backbone comprising a polyester as recited in amended claims 1 and 44". Furthermore, Applicants state that "while several paragraphs teach the use of esters as penetration enhancers (e.g., paragraphs 106 and 168) and pharmaceutically acceptable carriers (e.g., paragraph 133), these esters are not in the form of a polyester and are not a part of a polymeric backbone". Additionally, Applicants argue that "the use of poly(orthoesters) (e.g., paragraph 155) is only in the context of a matrix to encapsulate the subject compounds (e.g., the polyplexes)". Thus, Applicants submit that "Lollo does not teach or suggest a nanoparticle forming a micelle, wherein the nanoparticle

Art Unit: 1636

comprises a polymer having a backbone comprising a polyester, as recited in claims 1 and 44".

**Applicants arguments** have been fully considered but are not persuasive for reasons of record and presented herein. Specifically, Applicants argue that the amended claims now include a nanoparticle "comprising a polymer having a backbone comprising a polyester" that is not taught or suggested by Lollo et al. However, as stated above, claims must be given their broadest reasonable interpretation in light of the instant specification and therefore the phrase "a polymer having a backbone comprising a polyester" does not necessarily require a polyester backbone but rather a backbone comprising a polyester. For example, Applicants recite: "In one embodiment, the core shell nanoparticle may be made from a polymeric compound. The polymeric compound may include a portion capable of associating a nucleic acid and a second portion capable of associating a drug. The polymeric compound may be a branched polymeric compound and the branches may be grafted onto a backbone (instant specification, PgPub ¶ 0068). Therefore, the polyester component may be a side-chain or branch or otherwise associated component to any backbone molecule and Applicants argument that the statement of Lollo et al (¶ 0064) reciting "Typically, polymeric chains (such as 'A' and 'B' above) are grafted to amino groups on proteins, cationic polymers, or more specifically poly-L-lysine (e.g., 'C' above) using activated esters" is not relevant because these activated ester reactions produces "an amide bond linked conjugate" is not persuasive.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 3-5, 8-16, 44 and 49-54 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lollo et al (see above, of record), as applied to the claims above, in view of Pistel et al in "Brush-like branched biodegradable polyesters, part III: Protein release from microspheres of poly(vinyl alcohol)-graft-poly(D,L-lactic-co-glycolic acid)" (Journal of Controlled Release; 2001, Vol. 73:pages 7-20).

Claims are as described above and are taught by Lollo et al for the reasons above. As stated above, the claims may be interpreted broadly to be taught by Lollo et al for the reasons provided above. However, in an alternative interpretation of the amended claims, as argued by Applicant in REMARKS, Lollo et al does not explicitly teach a polyester backbone.

Pistel et al teach articles for delivering a drug comprising a nanoparticle forming a micelle, wherein the nanoparticle comprises a polymer having a backbone comprising a polyester. Pistel et al teach microencapsulation of hydrophilic macromolecules, such as proteins and FITC-dextran for a model system for parenteral drug delivery. Pistel et al recite "brush-like branched polyesters, obtained by grafting poly(lactic-co-glycolic acid), PLGA, onto water-soluble poly(vinyl alcohol) (PVAL) backbones, were investigated regarding their utility for microencapsulation of proteins (e.g. abstract).

It would have been obvious to one of ordinary skill in the art to have used the polyester backbone of Pistel et al in the article of Lollo et al because Pistel et al state that their microencapsulation of hydrophilic macromolecules using a polyester backbone was a model system for parenteral drug delivery.

One of ordinary skill in the art would have been motivated to use the polyester backbone of Pistel et al in the article of Lollo et al because Pistel et al state that "grafting polyester chains onto hydrophilic backbones" yields polymers that allow manipulation of their hydrophilicity and hence compatibility with proteins in a broad range and also can control degradation and release rates (e.g. page 8, ¶¶ bridging left and right columns).

Absent evidence to the contrary, one would have a reasonable expectation of success combining the teachings of the art because the use of polyester backbones for the purpose of micellar drug delivery was routinely practiced at the time of the teachings of Lollo et al and Pistel et al.

In view of the foregoing, the method of claims 1, 3-5, 8-16, 44 and 49-54 as a whole, would have been obvious to one of ordinary skill in the art at the time the invention was made. Therefore, the claims are properly rejected under 35 USC §103(a).

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERINE S. HIBBERT whose telephone number is (571)270-3053. The examiner can normally be reached on M-F 8AM-5PM, EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Respectfully submitted,

Catherine S. Hibbert, PhD  
Examiner/AU1636

/ Christopher S. F. Low /  
Supervisory Patent Examiner, Art Unit 1636